Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(2-phenyl-2-ethoxy)ethyl-4-(2-benzyloxy)propylpiperazine
2. 1-(2-phenyl-2-ethoxy)ethyl-4-(3-phenyl-2-methyl-3-propanone)piperazine
3. 3-(4-(beta-ethoxyphenethyl)-1-piperazinyl)-2-methylpropiophenone
4. 746 Ce
5. Eftapan
6. Eprazinone
7. Eprazinone Dihydrochloride, 3-(14)c-labeled
8. Eprazinone Hydrochloride
1. 10402-53-6
2. Eprazinone Hydrochloride
3. Eftapan
4. Resplen
5. 3-(4-(2-ethoxy-2-phenylethyl)piperazin-1-yl)-2-methyl-1-phenylpropan-1-one Dihydrochloride
6. Mucitux
7. Eprazinone Hcl
8. Nsc 317935
9. Eprazinone Hydrochloride [jan]
10. Eprazinone (dihydrochloride)
11. Chebi:31551
12. 394x1l8i9y
13. 1-(2-benzoylpropyl)-2-(2-ethoxy-2-phenylethyl)piperazine Dihydrochloride
14. 1-(2-phenyl-2-ethoxy)ethyl-4-(2-benzyloxy)propylpiperazine Dihydrochloride
15. 2-(4-(beta-ethoxyphenethyl)-1-piperazinylmethyl)propiophenone Dihydrochloride
16. Dsstox_cid_26631
17. Dsstox_rid_81779
18. Dsstox_gsid_46631
19. Eprazinone Hydrochloride (jan)
20. 3-(4-(2-ethoxy-2-phenylethyl)piperazin-1-yl)-2-methyl-1-phenylpropan-1-one 2hcl
21. 3-[4-(2-ethoxy-2-phenylethyl)piperazin-1-yl]-2-methyl-1-phenylpropan-1-one Dihydrochloride
22. Cas-10402-53-6
23. Nsc-317935
24. Ncgc00167445-01
25. Einecs 233-872-8
26. 746 Ce
27. Unii-394x1l8i9y
28. Eprazinone Dihcl
29. Resplen (tn)
30. Eprazinonedihydrochloride
31. 1-propanone, 3-(4-(2-ethoxy-2-phenylethyl)-1-piperazinyl)-2-methyl-1-phenyl-, Dihydrochloride
32. 3-(4-(2-ethoxy-2-phenylethyl)-1-piperazinyl)-2-methyl-1-phenyl-1-propanone Dihydrochloride
33. 3-(4-(beta-ethoxyphenethyl)-1-piperazinyl)-2-methyl-1-propiophenone Dihydrochloride
34. Chembl2359721
35. Dtxsid1046631
36. Schembl21807703
37. Hy-b2078a
38. Bcp13485
39. Tox21_112449
40. Mfcd01695215
41. S4137
42. Akos016008437
43. Tox21_112449_1
44. Ac-8087
45. Ccg-269264
46. Ds-3924
47. Eprazinone Dihydrochloride [mi]
48. 3-(4-(beta-ethoxyphenethyl)-1-piperazinyl)-2-methylpropiophenone Dihydrochloride
49. Eprazinone Hydrochloride [mart.]
50. Propiophenone, 2-(4-(beta-ethoxyphenethyl)-1-piperazinyl)methyl-, Dihydrochloride
51. Eprazinone Hydrochloride [who-dd]
52. Ncgc00167445-02
53. Cs-0019683
54. D01106
55. 402e536
56. A896306
57. Q27104199
58. 1-(2-ethoxy-2-phenylethyl)-4-(2-methyl-3-oxo-3-phenylpropyl)piperazinediium Dichloride
59. 3-(4-(.beta.-ethoxyphenethyl)piperazin-1-yl)-2-methylpropiophenone Dihydrochloride
60. 1-(2-benzoylpropyl)-4-(2-ethoxy-2-phenylethyl)piperazine Dihydrochloride; 3-[4-(2-ethoxy-2-phenylethyl)piperazin-1-yl]-2-methyl-1-phenylpropan-1-one Dihydrochloride;eprazinone 2hcl
| Molecular Weight | 453.4 g/mol |
|---|---|
| Molecular Formula | C24H34Cl2N2O2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 9 |
| Exact Mass | 452.1997337 g/mol |
| Monoisotopic Mass | 452.1997337 g/mol |
| Topological Polar Surface Area | 32.8 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 450 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Expectorants
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)
Market Place
ABOUT THIS PAGE
A 10402-53-6 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 10402-53-6, including repackagers and relabelers. The FDA regulates 10402-53-6 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 10402-53-6 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 10402-53-6 supplier is an individual or a company that provides 10402-53-6 active pharmaceutical ingredient (API) or 10402-53-6 finished formulations upon request. The 10402-53-6 suppliers may include 10402-53-6 API manufacturers, exporters, distributors and traders.
click here to find a list of 10402-53-6 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 10402-53-6 Drug Master File in Japan (10402-53-6 JDMF) empowers 10402-53-6 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 10402-53-6 JDMF during the approval evaluation for pharmaceutical products. At the time of 10402-53-6 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 10402-53-6 suppliers with JDMF on PharmaCompass.
10402-53-6 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 10402-53-6 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 10402-53-6 GMP manufacturer or 10402-53-6 GMP API supplier for your needs.
A 10402-53-6 CoA (Certificate of Analysis) is a formal document that attests to 10402-53-6's compliance with 10402-53-6 specifications and serves as a tool for batch-level quality control.
10402-53-6 CoA mostly includes findings from lab analyses of a specific batch. For each 10402-53-6 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
10402-53-6 may be tested according to a variety of international standards, such as European Pharmacopoeia (10402-53-6 EP), 10402-53-6 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (10402-53-6 USP).
LOOKING FOR A SUPPLIER?
